Adipocyte G


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
12 06 2020
Historique:
received: 02 09 2019
accepted: 18 05 2020
entrez: 14 6 2020
pubmed: 14 6 2020
medline: 25 8 2020
Statut: epublish

Résumé

Adipocyte dysfunction links obesity to insulin resistance and type 2 diabetes. Adipocyte function is regulated by receptor-mediated activation of heterotrimeric G proteins. Little is known about the potential in vivo metabolic roles of G

Identifiants

pubmed: 32532984
doi: 10.1038/s41467-020-16756-x
pii: 10.1038/s41467-020-16756-x
pmc: PMC7293267
doi:

Substances chimiques

Blood Glucose 0
Insulin 0
GTP-Binding Protein alpha Subunits, Gi-Go EC 3.6.5.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2995

Références

Guilherme, A., Virbasius, J. V., Puri, V. & Czech, M. P. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 9, 367–377 (2008).
pubmed: 18401346 pmcid: 2886982 doi: 10.1038/nrm2391
Gonzalez-Muniesa, P. et al. Obesity. Nat. Rev. Dis. Prim. 3, 17034 (2017).
pubmed: 28617414 doi: 10.1038/nrdp.2017.34
Kusminski, C. M., Bickel, P. E. & Scherer, P. E. Targeting adipose tissue in the treatment of obesity-associated diabetes. Nat. Rev. Drug Disco. 15, 639–660 (2016).
doi: 10.1038/nrd.2016.75
Saltiel, A. R. & Olefsky, J. M. Inflammatory mechanisms linking obesity and metabolic disease. J. Clin. Invest 127, 1–4 (2017).
pubmed: 28045402 pmcid: 5199709 doi: 10.1172/JCI92035
Guh, D. P. et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC public health 9, 88 (2009).
pubmed: 19320986 pmcid: 2667420 doi: 10.1186/1471-2458-9-88
Amisten, S. et al. An atlas of G-protein coupled receptor expression and function in human subcutaneous adipose tissue. Pharm. Ther. 146, 61–93 (2015).
doi: 10.1016/j.pharmthera.2014.09.007
Regard, J. B., Sato, I. T. & Coughlin, S. R. Anatomical profiling of G protein-coupled receptor expression. Cell 135, 561–571 (2008).
pubmed: 18984166 pmcid: 2590943 doi: 10.1016/j.cell.2008.08.040
Ghorbani, M. & Himms-Hagen, J. Appearance of brown adipocytes in white adipose tissue during CL 316,243-induced reversal of obesity and diabetes in Zucker fa/fa rats. Int. J. Obes. Relat. Metab. Disord.: J. Int. Assoc. Study Obes. 21, 465–475 (1997).
doi: 10.1038/sj.ijo.0800432
Xiao, C., Goldgof, M., Gavrilova, O. & Reitman, M. L. Anti-obesity and metabolic efficacy of the beta3-adrenergic agonist, CL316243, in mice at thermoneutrality compared to 22 degrees C. Obes. (Silver Spring, Md.) 23, 1450–1459 (2015).
doi: 10.1002/oby.21124
Himms-Hagen, J. et al. Effect of CL-316,243, a thermogenic beta 3-agonist, on energy balance and brown and white adipose tissues in rats. Am. J. Physiol. 266, R1371–R1382 (1994).
pubmed: 7910436
Collins, S. & Surwit, R. S. The beta-adrenergic receptors and the control of adipose tissue metabolism and thermogenesis. Recent Prog. Horm. Res. 56, 309–328 (2001).
pubmed: 11237219 doi: 10.1210/rp.56.1.309
Wang, L. et al. Selective activation of Gs signaling in adipocytes causes striking metabolic improvements in mice. Mol. Metab. https://doi.org/10.1016/j.molmet.2019.06.018 (2019).
Caron, A. et al. Adipocyte Gs but not Gi signaling regulates whole-body glucose homeostasis. Mol. Metab. https://doi.org/10.1016/j.molmet.2019.06.019 (2019).
Ruiz de Azua, I. et al. Adipocyte cannabinoid receptor CB1 regulates energy homeostasis and alternatively activated macrophages. J. Clin. Invest 127, 4148–4162 (2017).
pubmed: 29035280 pmcid: 5663356 doi: 10.1172/JCI83626
Offermanns, S. Free fatty acid (FFA) and hydroxy carboxylic acid (HCA) receptors. Annu Rev. Pharm. Toxicol. 54, 407–434 (2014).
doi: 10.1146/annurev-pharmtox-011613-135945
Lukasova, M., Hanson, J., Tunaru, S. & Offermanns, S. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials. Trends Pharm. Sci. 32, 700–707 (2011).
pubmed: 21944259 doi: 10.1016/j.tips.2011.08.002
Wettschureck, N. & Offermanns, S. Mammalian G proteins and their cell type specific functions. Physiological Rev. 85, 1159–1204 (2005).
doi: 10.1152/physrev.00003.2005
Armbruster, B. N., Li, X., Pausch, M. H., Herlitze, S. & Roth, B. L. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc. Natl Acad. Sci. USA 104, 5163–5168 (2007).
pubmed: 17360345 doi: 10.1073/pnas.0700293104
Rogan, S. C. & Roth, B. L. Remote control of neuronal signaling. Pharm. Rev. 63, 291–315 (2011).
pubmed: 21415127 doi: 10.1124/pr.110.003020
Eguchi, J. et al. Transcriptional control of adipose lipid handling by IRF4. Cell Metab. 13, 249–259 (2011).
pubmed: 21356515 pmcid: 3063358 doi: 10.1016/j.cmet.2011.02.005
Regard, J. B. et al. Probing cell type-specific functions of Gi in vivo identifies GPCR regulators of insulin secretion. J. Clin. Invest 117, 4034–4043 (2007).
pubmed: 17992256 pmcid: 2066199
Kraemer, F. B. & Shen, W. J. Hormone-sensitive lipase: control of intracellular tri-(di-)acylglycerol and cholesteryl ester hydrolysis. J. Lipid Res 43, 1585–1594 (2002).
pubmed: 12364542 doi: 10.1194/jlr.R200009-JLR200
Cerk, I. K., Wechselberger, L. & Oberer, M. Adipose triglyceride lipase regulation: an overview. Curr. Protein Pept. Sci. 19, 221–233 (2018).
pubmed: 28925902
Ayala, J. E. et al. Hyperinsulinemic-euglycemic clamps in conscious, unrestrained mice. J. Vis. Exp. https://doi.org/10.3791/3188 (2011).
Boden, G. Obesity and free fatty acids. Endocrinol. Metab. Clin. North Am. https://doi.org/10.1016/j.ecl.2008.06.007 (2008).
Girousse, A. et al. Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass. PLoS Biol. 11, e1001485 (2013).
pubmed: 23431266 pmcid: 3576369 doi: 10.1371/journal.pbio.1001485
Claus, T. H. et al. Specific inhibition of hormone-sensitive lipase improves lipid profile while reducing plasma glucose. J. Pharmacol. Exp. therapeutics 315, 1396–1402 (2005).
doi: 10.1124/jpet.105.086926
Kwon, H. & Pessin, J. E. Adipokines mediate inflammation and insulin resistance. Front Endocrinol. (Lausanne) 4, 71 (2013).
doi: 10.3389/fendo.2013.00071
Jung, U. J. & Choi, M. S. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J. Mol. Sci. 15, 6184–6223 (2014).
pubmed: 24733068 pmcid: 4013623 doi: 10.3390/ijms15046184
Lumeng, C. N. & Saltiel, A. R. Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 121, 2111–2117 (2011).
pubmed: 21633179 pmcid: 3104776 doi: 10.1172/JCI57132
Reilly, S. M. & Saltiel, A. R. Adapting to obesity with adipose tissue inflammation. Nat. Rev. Endocrinol. 13, 633–643 (2017).
pubmed: 28799554 doi: 10.1038/nrendo.2017.90
Dalle, S., Ricketts, W., Imamura, T., Vollenweider, P. & Olefsky, J. M. Insulin and insulin-like growth factor I receptors utilize different G protein signaling components. J. Biol. Chem. 276, 15688–15695 (2001).
pubmed: 11278773 doi: 10.1074/jbc.M010884200
Kreuzer, J., Nurnberg, B. & Krieger-Brauer, H. I. Ligand-dependent autophosphorylation of the insulin receptor is positively regulated by Gi-proteins. Biochem. J. 380, 831–836 (2004).
pubmed: 15025562 pmcid: 1224225 doi: 10.1042/bj20031659
Rozengurt, E., Sinnett-Smith, J. & Kisfalvi, K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin. Cancer Res. 16, 2505–2511 (2010).
pubmed: 20388847 pmcid: 2862089 doi: 10.1158/1078-0432.CCR-09-2229
Xu, E., Schwab, M. & Marette, A. Role of protein tyrosine phosphatases in the modulation of insulin signaling and their implication in the pathogenesis of obesity-linked insulin resistance. Rev. Endocr. Metab. Disord. 15, 79–97 (2014).
pubmed: 24264858 doi: 10.1007/s11154-013-9282-4
Owen, C. et al. Adipocyte-specific protein tyrosine phosphatase 1B deletion increases lipogenesis, adipocyte cell size and is a minor regulator of glucose homeostasis. PLoS ONE 7, e32700 (2012).
pubmed: 22389718 pmcid: 3289674 doi: 10.1371/journal.pone.0032700
Xie, L. et al. Cellular effects of small molecule PTP1B inhibitors on insulin signaling. Biochemistry 42, 12792–12804 (2003).
pubmed: 14596593 doi: 10.1021/bi035238p
Zhang, S. & Zhang, Z. Y. PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. Drug Disco. Today 12, 373–381 (2007).
doi: 10.1016/j.drudis.2007.03.011
Tao, J., Malbon, C. C. & Wang, H. Y. Insulin stimulates tyrosine phosphorylation and inactivation of protein-tyrosine phosphatase 1B in vivo. J. Biol. Chem. 276, 29520–29525 (2001).
pubmed: 11395511 doi: 10.1074/jbc.M103721200
Brautigan, D. L. & Pinault, F. M. Activation of membrane protein-tyrosine phosphatase involving cAMP- and Ca2+/phospholipid-dependent protein kinases. Proc. Natl Acad. Sci. USA 88, 6696–6700 (1991).
pubmed: 1650478 doi: 10.1073/pnas.88.15.6696
Krishnan, N. et al. PTP1B inhibition suggests a therapeutic strategy for Rett syndrome. J. Clin. Invest 125, 3163–3177 (2015).
pubmed: 26214522 pmcid: 4563751 doi: 10.1172/JCI80323
Zhu, H. et al. Cre-dependent DREADD (designer receptors exclusively activated by designer drugs) mice. Genes 54, 439–446 (2016).
doi: 10.1002/dvg.22949
Rossi, M. et al. Hepatic Gi signaling regulates whole-body glucose homeostasis. J. Clin. Invest 128, 746–759 (2018).
pubmed: 29337301 pmcid: 5785257 doi: 10.1172/JCI94505
Mottillo, E. P., Shen, X. J. & Granneman, J. G. Role of hormone-sensitive lipase in beta-adrenergic remodeling of white adipose tissue. Am. J. Physiol. Endocrinol. Metab. 293, E1188–E1197 (2007).
pubmed: 17711991 doi: 10.1152/ajpendo.00051.2007
Berglund, E. D. et al. Glucose metabolism in vivo in four commonly used inbred mouse strains. Diabetes 57, 1790–1799 (2008).
pubmed: 18398139 pmcid: 2453626 doi: 10.2337/db07-1615
Ayala, J. E., Bracy, D. P., McGuinness, O. P. & Wasserman, D. H. Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 55, 390–397 (2006).
pubmed: 16443772 doi: 10.2337/diabetes.55.02.06.db05-0686
Finegood, D. T., Bergman, R. N. & Vranic, M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes 36, 914–924 (1987).
pubmed: 3297886 doi: 10.2337/diab.36.8.914
Steele, R., Wall, J. S., De Bodo, R. C. & Altszuler, N. Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am. J. Physiol. 187, 15–24 (1956).
pubmed: 13362583 doi: 10.1152/ajplegacy.1956.187.1.15
Gautam, D. et al. Beneficial metabolic effects of M3 muscarinic acetylcholine receptor deficiency. Cell Metab. 4, 363–375 (2006).
pubmed: 17084710 doi: 10.1016/j.cmet.2006.09.008
Tanaka, N. et al. Adipocyte-specific disruption of fat-specific protein 27 causes hepatosteatosis and insulin resistance in high-fat diet-fed mice. J. Biol. Chem. 290, 3092–3105 (2015).
pubmed: 25477509 doi: 10.1074/jbc.M114.605980
Kazak, L. et al. A creatine-driven substrate cycle enhances energy expenditure and thermogenesis in beige fat. Cell 163, 643–655 (2015).
pubmed: 26496606 pmcid: 4656041 doi: 10.1016/j.cell.2015.09.035
Nakajima, K. & Wess, J. Design and functional characterization of a novel, arrestin-biased designer G protein-coupled receptor. Mol. Pharm. 82, 575–582 (2012).
doi: 10.1124/mol.112.080358
Kim, J. K., Gavrilova, O., Chen, Y., Reitman, M. L. & Shulman, G. I. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J. Biol. Chem. 275, 8456–8460 (2000).
pubmed: 10722680 doi: 10.1074/jbc.275.12.8456

Auteurs

Lei Wang (L)

Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 20892, USA.

Sai P Pydi (SP)

Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 20892, USA.

Lu Zhu (L)

Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 20892, USA.

Luiz F Barella (LF)

Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 20892, USA.

Yinghong Cui (Y)

Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 20892, USA.

Oksana Gavrilova (O)

Mouse Metabolism Core, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 20892, USA.

Kendra K Bence (KK)

Internal Medicine Research Unit, Worldwide Research, Development and Medical, Pfizer Inc, Cambridge, MA, 02139, USA.

Cecile Vernochet (C)

Internal Medicine Research Unit, Worldwide Research, Development and Medical, Pfizer Inc, Cambridge, MA, 02139, USA.

Jürgen Wess (J)

Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 20892, USA. jurgenw@niddk.nih.gov.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH